Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Deep Learning-Based Transfer Learning for Classification of Skin Cancer
149
Zitationen
6
Autoren
2021
Jahr
Abstract
One of the major health concerns for human society is skin cancer. When the pigments producing skin color turn carcinogenic, this disease gets contracted. A skin cancer diagnosis is a challenging process for dermatologists as many skin cancer pigments may appear similar in appearance. Hence, early detection of lesions (which form the base of skin cancer) is definitely critical and useful to completely cure the patients suffering from skin cancer. Significant progress has been made in developing automated tools for the diagnosis of skin cancer to assist dermatologists. The worldwide acceptance of artificial intelligence-supported tools has permitted usage of the enormous collection of images of lesions and benevolent sores approved by histopathology. This paper performs a comparative analysis of six different transfer learning nets for multi-class skin cancer classification by taking the HAM10000 dataset. We used replication of images of classes with low frequencies to counter the imbalance in the dataset. The transfer learning nets that were used in the analysis were VGG19, InceptionV3, InceptionResNetV2, ResNet50, Xception, and MobileNet. Results demonstrate that replication is suitable for this task, achieving high classification accuracies and F-measures with lower false negatives. It is inferred that Xception Net outperforms the rest of the transfer learning nets used for the study, with an accuracy of 90.48. It also has the highest recall, precision, and F-Measure values.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.525 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.115 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.678 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.811 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.365 Zit.